-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on BeOne Medicines, Lowers Price Target to $403

Benzinga·07/14/2026 11:02:21
Listen to the news
Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and lowers the price target from $409 to $403.